Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer

Article excerpt

Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy, including a near doubling of progression-free survival compared with expectations with standard of care, in previously treated patients with advanced NRG1-positive cholangiocarcinoma.